arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Erasca, Inc.

ERAS Health Care Biotechnology: Pharmaceutical Preparations
$14.04
▼ -4.0% Today
as of Oct 22, 16:48 ET
Last 30 days -13.12% Sep 14 → Oct 22
$13.16 $13.99 $14.82 $15.65 $16.48 Sep 14 Sep 22 Sep 29 Oct 07 Oct 14 Oct 22
Open
$14.22
High
$14.64
Low
$13.82
Volume
$2M
Avg Vol
$5M
Mkt Cap
$5.1B
P/E (TTM)
—
Beta
—
52w High
$24.28
52w Low
$2.10
Div Yield
—
Shares Out
$313M

Recent Press Releases & News last 60 days · 7 items

Oct 19 · 06:08 Simply Wall St.
Erasca (ERAS) Stock Looks Above Fair Value After Its 5x Run
Oct 16 · 15:32 MT Newswires
Erasca Chief Operating Officer to Depart; Shares Fall
Sep 10 · 12:00 PR GlobeNewswire
Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium
▸ Show all 7 press releases & news Free account →

ERAS earnings at a glance

The options market is pricing a move of about ±13.1% after the report, a range of roughly $12.20 to $15.88 from today's $14.04. Over its last 2 reports the stock rose the next day 1 time and fell 1, moving ±3.7% on average; after the most recent report on May 11, 2026 it moved +3.2%. That means options currently expect more movement than ERAS has typically delivered. ERAS beat the consensus EPS estimate in 2 of its last 4 reported quarters. Implied volatility is currently 111%. The share price of $14.04 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$2.10
$24
54% of range
Avg surprise (last 4)
+12.6%
Avg reaction (last 2)
-0.6%
50% positive
Latest IV / EM
111%
EM ±13.1% · $15 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.29$-0.24$-0.20$-0.15$-0.11 Actual $-0.22Actual $-0.21Actual $-0.20Actual $-0.23Actual $-0.29Actual $-0.11Actual $-0.11Est $-0.12Actual $-0.12Est $-0.12Actual $-0.11Est $-0.11Actual $-0.11Est $-0.19Actual $-0.14 MarJunSepMarJunSepMar/2025Jun/2025Sep/2025Mar/2026Jun
Revenue vs Net Income Revenue Net income
$-183M$-146M$-108M$-70M$-32M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.14 — — — — financials
Mon May 11, 2026Mar/2026 $-0.11 $-0.19 +42.1% 0.0% +3.2% earnings
Wed Nov 12, 2025Sep/2025 $-0.11 $-0.11 0.0% — — earnings
Tue Aug 12, 2025Jun/2025 $-0.12 $-0.12 0.0% — — earnings
Tue May 13, 2025Mar/2025 $-0.11 $-0.12 +8.3% — -4.3% earnings
Mon Sep 30, 2024Sep 2024 $-0.11 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.29 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.23 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.20 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.21 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.22 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-48M$-188M—$-35M$-38M$-36M—$-37M
Net income$-44M$-183M—$-31M$-34M$-31M—$-31M
EPS (diluted)$-0.14$-0.60—$-0.11$-0.12$-0.11—$-0.11

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$43M$47M$74M$70M$66M$70M$68M$69M
Inventory————————
Total current assets$278M$254M$286M$300M$311M$315M$309M$330M
Total assets$435M$461M$396M$420M$445M$471M$503M$529M
Long-term debt————————
Total liabilities$73M$68M$71M$73M$73M$72M$79M$79M
Total equity$362M$394M$325M$348M$372M$400M$423M$450M

Implied volatility — last 90 days

51%143%234%326%417% Jun 07 — IV 103% · EM ±14.2%Jun 08 — IV 92% · EM ±12.2%Jun 09 — IV 101% · EM ±12.7%Jun 10 — IV 104% · EM ±12.3%Jun 11 — IV 107% · EM ±11.8%Jun 12 — IV 99% · EM ±10.1%Jun 15 — IV 108% · EM ±7.8%Jun 16 — IV 418% · EM ±24.7%Jun 17 — IV 377% · EM ±15.7%Jun 19 — IV 90% · EM ±19.9%Jun 22 — IV 83% · EM ±17.4%Jun 23 — IV 85% · EM ±17.4%Jun 24 — IV 87% · EM ±17.5%Jun 25 — IV 86% · EM ±16.9%Jun 26 — IV 82% · EM ±15.8%Jun 29 — IV 108% · EM ±19.1%Jun 30 — IV 98% · EM ±16.8%Jul 01 — IV 96% · EM ±16.1%Jul 02 — IV 93% · EM ±15.0%Jul 03 — IV 96% · EM ±15.0%Jul 06 — IV 113% · EM ±15.6%Jul 07 — IV 105% · EM ±13.9%Jul 08 — IV 102% · EM ±12.7%Jul 09 — IV 97% · EM ±11.5%Jul 10 — IV 109% · EM ±12.0%Jul 13 — IV 125% · EM ±10.5%Jul 14 — IV 105% · EM ±7.6%Jul 15 — IV 263% · EM ±15.5%Jul 16 — IV 172% · EM ±7.2%Jul 20 — IV 103% · EM ±24.4%Jul 21 — IV 106% · EM ±24.6%Jul 22 — IV 105% · EM ±24.0%Jul 23 — IV 104% · EM ±23.4%Jul 24 — IV 102% · EM ±22.6%Jul 27 — IV 107% · EM ±22.3%Jul 28 — IV 118% · EM ±24.1%Jul 29 — IV 88% · EM ±17.6%Jul 30 — IV 118% · EM ±23.2%Jul 31 — IV 113% · EM ±21.6%Aug 03 — IV 112% · EM ±19.8%Aug 04 — IV 117% · EM ±20.1%Aug 05 — IV 110% · EM ±18.4%Aug 06 — IV 117% · EM ±18.9%Aug 07 — IV 148% · EM ±23.1%Aug 10 — IV 119% · EM ±16.5%Aug 11 — IV 120% · EM ±15.9%Aug 12 — IV 107% · EM ±13.5%Aug 13 — IV 97% · EM ±11.5%Aug 14 — IV 104% · EM ±11.5%Aug 17 — IV 120% · EM ±10.0%Aug 18 — IV 124% · EM ±9.0%Aug 19 — IV 138% · EM ±8.2%Aug 20 — IV 182% · EM ±7.6%Aug 24 — IV 93% · EM ±19.5%Aug 25 — IV 99% · EM ±20.3%Aug 26 — IV 105% · EM ±21.0%Aug 27 — IV 105% · EM ±20.7%Aug 28 — IV 98% · EM ±18.7%Aug 31 — IV 101% · EM ±17.9%Sep 01 — IV 108% · EM ±18.6%Sep 02 — IV 111% · EM ±18.5%Sep 03 — IV 108% · EM ±17.5%Sep 04 — IV 100% · EM ±15.6%Sep 07 — IV 113% · EM ±15.6%Sep 08 — IV 131% · EM ±17.4%Sep 09 — IV 112% · EM ±14.0%Sep 10 — IV 162% · EM ±19.1%Sep 11 — IV 121% · EM ±13.4%Sep 14 — IV 52% · EM ±4.3%Sep 15 — IV 151% · EM ±11.0%Sep 16 — IV 146% · EM ±8.6%Sep 17 — IV 159% · EM ±6.6%Sep 21 — IV 96% · EM ±19.9%Sep 22 — IV 88% · EM ±18.0%Sep 23 — IV 101% · EM ±20.3%Sep 24 — IV 91% · EM ±17.9%Sep 25 — IV 89% · EM ±17.1%Sep 28 — IV 91% · EM ±16.1%Sep 29 — IV 102% · EM ±17.6%Sep 30 — IV 94% · EM ±15.7%Oct 01 — IV 102% · EM ±16.5%Oct 02 — IV 99% · EM ±15.4%Oct 06 — IV 103% · EM ±13.6%Oct 07 — IV 110% · EM ±13.8%Oct 08 — IV 111% · EM ±13.1%

Sector peers

COGT
Cogent Biosciences, Inc.
$5.2B $31.31+0.2%
PTCT
PTC Therapeutics, Inc.
$5.3B $63.04+0.2%
DNTH
Dianthus Therapeutics, Inc.
$4.7B $78.53-0.3%
GMAB
Genmab A/S
$4.7B $40.00+2.4%
LGND
Ligand Pharmaceuticals Incorporated
$5.8B $307.82+0.5%
INDV
Indivior Pharmaceuticals, Inc.
$4.3B $35.33+1.6%

ERAS earnings FAQ

What is ERAS's expected move for earnings?

Options currently price a move of about ±13.1%, or $1.84 per share either way from $14.04.

How does ERAS stock usually react to earnings?

Across the last 2 reports the average next-day move was ±3.7%, up 1 times and down 1 times.

What is ERAS's implied volatility?

ERAS's at-the-money implied volatility is about 111% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in